

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-742-O (400/144)	Serial No. 10/764,957
	Applicant: McSwiggen et al.	
	Filing Date: January 26, 2004	Group: 1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2004/0161844	11/04/03	Baker et al.			08/19/04
	*	US-2005/0020521	09/25/03	Rana, Tariq M.			01/27/05
	*	US-2005/0171039	05/11/04	McSwiggen et al.			08/04/05
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
	*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,587,471	12/24/96	Cook et al.			
	*	6,214,805	04/10/01	Torrence et al.			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-742-O (400/144)	Serial No. 10/764,957
	Applicant: McSwiggen et al.	
	Filing Date: January 26, 2004	Group: 1635

	*	7,078,196	07/18/06	Tuschl et al.			
	*	5,998,148	12/07/99	Bennett et al.			
	*	5,998,206	12/07/99	Cowser			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,824,972	11/30/04	Kenwick et al.			
	*	7,022,828	04/04/06	McSwiggen et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclasses	Translation	
							Yes	No
	1.	1389637	08/05/02	EP (Klippel et al.)				
	2.	03/044188	05/30/03	WO (Tei et al.)				
	3.	04/029212	04/08/04	WO (Rana, Tariq M.)				
	4.	04/090105	10/21/04	WO (Leake et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	5.	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
	6.	Bellon et al., "4-Thio-oligo- β -D-ribonucleotides: synthesis of β -4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-742-O (400/144)	Serial No. 10/764,957
	Applicant: McSwiggen et al.	
	Filing Date: January 26, 2004	Group: 1635

7.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (2001)
8.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
9.	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
10.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
11.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
12.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
13.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
14.	Hornung et al., "Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
15.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
16.	Kawaski et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> , 36, 831-841 (1993)
17.	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
18.	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
19.	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-742-O (400/144)	Serial No. 10/764,957
	Applicant: McSwiggen et al.	
	Filing Date: January 26, 2004	Group: 1635

20.	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)
21.	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
22.	Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
23.	Pavco et al., "Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors," <u>Clinical Cancer Research</u> 6:2094-2103 (2000)
24.	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <u>Nucleic Acids Research</u> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
25.	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>Journal of Biological Chemistry</i> , 278, 7108-7118 (2003)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.